NEBCIN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jun 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEBCIN is an injectable small-molecule antibiotic approved in 1975 by Eli Lilly and Company. The specific indication and mechanism of action are not publicly documented in this dataset. It is administered via injection and represents a legacy NDA-approved therapeutic.
LOE Approaching
Product is approaching loss of exclusivity with competitive pressure rated at 30%, indicating declining brand team investment and shrinking commercial infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NEBCIN currently has zero linked job openings, reflecting its advanced lifecycle stage and approaching loss of exclusivity. Career roles on this product are limited to maintenance and legacy-brand management, with minimal growth opportunity and declining headcount trajectory.
Brand ManagerField Sales Representative
Worked on NEBCIN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.